NewBiologix expands to the U.S. with new subsidiary

NewBiologix, a Switzerland-based technology company that focuses on scalable production of viral vectors for gene and cell therapy, has launched a new U.S. subsidiary.

The new U.S. hub, located in Delaware, will offer real-time support and collaboration for gene and cell therapy companies in the world’s largest biotech market.

NewBiologix has appointed David Kelly to lead the U.S. operation and head business development. Kelly, with more than a decade of experience in gene and cell therapy as well as stem cell manufacturing and commercial development, will oversee sales and support for NewBiologix services and licensing opportunities for clients across the U.S. and Canada.

NewBiologix emerged from stealth mode last year with a proprietary platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company is currently focused on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapies. Specifically, the company’s technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines which will be engineered to be readily adaptable to meet the industry’s viral vector demands.